A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once‐daily injection in patients with well‐controlled type 2 diabetes

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|7|831-838

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.7, 2015-07, pp. : 831-838

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study

By Meneghini L. F.   Dornhorst A.   Sreenan S.  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 1029-1035

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1056-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

By Strojek Krzysztof   Bebakar Wan M.W.   Khutsoane Duma T.   Pesic Milica   Šmahelová Alena   Thomsen Henrik F.   Kalra Sanjay  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2887-2894

Informa Healthcare

Access to resources Recommend Favorite

Weight‐neutral effect of insulin detemir

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 2, 2015-03 ,pp. : 222-230

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 699-702

John Wiley & Sons Inc

Access to resources Recommend Favorite